The Business of Biofabrication

Nurami Medical, a Haifa‐based biomedical startup, has closed a $30 million funding round to advance its innovative approach to meningeal tissue repair. The company, led by co-founder Nora Nseir and her partner Dr. Amir Bahar, is focused on developing products that support the regeneration of meningeal tissue following complex brain and spinal cord surgeries.

The startup has developed two products. One features a nanofiber patch designed to temporarily replace damaged meningeal tissue, while the other employs a suture-free adhesive technology that eliminates the need for stitching during surgery. The first product has already received FDA approval after a decade of research and development, and the second is currently in the animal testing phase with plans for human trials on the horizon.

The new investment will be used to nearly double the company’s workforce and expand its operational capabilities. Plans include the construction of a commercial manufacturing facility, a new research and development laboratory, and high-grade clean rooms that will support production. These enhancements are expected to enable the manufacture of up to 40,000 units per year, positioning Nurami Medical to scale its operations as it transitions from development to full-scale production and commercialization.

Nurami Medical’s technology addresses a critical challenge in neurosurgery—cerebrospinal fluid leakage—which can prolong hospital stays and increase the risk of complications. With a significant market in neurosurgical procedures valued at approximately $1 billion and potential applications in additional clinical areas, the company’s advancements could have far-reaching implications in the field of medical innovation.

For more info check out their website.